Sign in
Taking people in United StatesNo phase

Reduction or Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)

Key facts

Who runs it
InnovHeart
Where
Los Angeles, New York, Portland, Sacramento, and Thousand Oaks, United StatesSee the 5 sites
Trial code
Status
Recruiting
People taking part
15 people, planned
Started
5 Aug 2026
Expected to end
Sept 2032
Type of study
Interventional
Treatments tested
  • Mitral Valve Replacement
Record updated
10 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 50 criteriaShow less

Who can take part

  • Age 18 years or older
  • Symptomatic, moderate to severe or severe, functional or mixed, mitral regurgitation (≥ Grade 3+)
  • NYHA functional Class ≥ II. If Class IV, patient must be ambulatory
  • Ability to tolerate oral anticoagulation
  • Ability to qualify for bailout surgery (which may include open heart surgery)
  • High risk for open-heart mitral valve surgery due to age, co-morbidities or frailty, as determined by the Heart Team
  • Willing and able to complete study-related assessments and questionnaires

Who cannot take part

  • Endocarditis in the 3 months prior to procedure date
  • COPD on home oxygen therapy deemed too high risk for intubation
  • Myocardial infarction during prior 30 days
  • Stroke or TIA during prior 90 days
  • Severe extracardiac arteriopathy (safety measure for extra-circulatory support if surgical conversion is needed)
  • Prior mitral valve treatment (e.g., valve repair or replacement, MitraClip, etc.), and/or anticipated mitral valve treatment prior to enrollment
  • Prior surgical mechanical valve AVR
  • Prior TAVI. -Need for any planned cardiovascular surgery or intervention (other than for MV disease) within 30 days post-index procedure
  • CRT, CRT-D, IPG or ICD implanted in previous 30 days
  • Cardiogenic shock, hemodynamic instability, Systolic Blood Pressure <90mmHg, Inotropic dependent or IABP/mechanical circulatory support; CABG or PCI within previous 30 days
  • Prior or planned heart transplantation (UNOS status 1)
  • Excessive frailty or comorbid conditions that preclude the anticipated benefit of the mitral valve replacement
  • Life expectancy <1 yr. due to noncardiac conditions
  • Current admission with acute heart failure exacerbation
  • Active systemic infection
  • Severe pulmonary arterial hypertension (PAH), defined as PASP > 70mmHg
  • Documented bleeding or coagulation disorders (hypo- or hyper-coagulable states)
  • Severe connective tissue disease under chronic immunosuppressive or cortisone therapy
  • Inadequately treated for cardiac condition per applicable standards, such as for coronary artery disease, left ventricular dysfunction, mitral regurgitation, or heart failure, as reviewed by the Patient Screening Committee
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or other structural heart disease causing heart failure with the exception of dilated ischemic or non-ischemic cardiomyopathy; Procedural Exclusion Criteria
  • Known hypersensitivity or contraindication to procedural or post-procedural medication (e.g., contrast solution, anticoagulation therapy)
  • Documented hypersensitivity to nickel or titanium; Cardiac Imaging Exclusion Criteria (evaluated by Core Labs)
  • Chronic renal failure defined as eGFR < 30 mL/min/m2 or on renal replacement therapy
  • Platelets < 90,000
  • Purely degenerative (organic/primary) (i.e. intrinsic valve lesions) mitral regurgitation
  • Dependency on inotropic agents or mechanical circulatory support
  • Untreated clinically significant CAD
  • Modified Rankin Scale ≥4 disability
  • Refuses blood transfusions
  • Participating in other investigational studies likely to confound the results or affect the study
  • Unable or does not sign the study informed consent form
  • Patients classified as "vulnerable patients"; Cardiovascular Exclusion Criteria
  • Physical evidence of right-sided CHF:; Patients with ascites; Patients with anasarca (generalized edema / hydropsy)
  • Contraindications to TEE imaging
  • Left ventricular EF ≤ 30% by echocardiogram
  • Severe mitral annular calcification, severe mitral stenosis, valvular vegetation or mass
  • Extensive mitral flail leaflets
  • Evidence of new or untreated intracardiac thrombus, mass, or vegetation
  • Severe right ventricular dysfunction
  • Severe tricuspid regurgitation
  • Hemodynamically significant inter-atrial shunt (ASD)
  • Severe aortic regurgitation or aortic stenosis
  • Anatomic ineligibility for SATURN Valve or SATURN TS procedure as determined by the Screening Committee

Where in United States

  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Mitch GheorghiuNot yet recruiting
  • Columbia University Irving Medical Center/New York Presbyterian HospitalNew York, United StatesContact: Treena WilliamsTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: Amy KoskiNot yet recruiting
  • UC Davis HealthSacramento, United StatesContact: Kaelyn Tuerner-LeeNot yet recruiting
  • Los Robles Regional Medical CenterThousand Oaks, United StatesContact: Reas SolomonTaking people

About the trial

What the trial wants to find out

CASSINI-US is a prospective, single-arm, multicenter early feasibility study enrolling up to 15 patients at up to 5 sites in the United States (US).

Read full original descriptionShow less

The purpose of the study is to evaluate the technical (implant) feasibility, and safety, and performance of the SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation through a transcatheter approach.

Primary objectives evaluate the implant feasibility, and acute safety and performance of the SATURN TS TMVR System. The secondary objective and additional outcome measures characterize the long-term safety and performance of the SATURN TS TMVR System.

The group in the trial

  • SATURN TMVR CohortTreatment being tested

    Saturn transseptal TMVR System implant

    Treatment: Mitral Valve Replacement

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Reduction or Elimination of Mitral Regurgitation With the SATURN Trans-septal TMVR System in Patients With Severe, Symptomatic Mitral Regurgitation (Cassini-US)
Record updated
10 August 2026